2020 Nicotine Addiction Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs
The 2020 Nicotine Addiction pipeline report presents a comprehensive overview of the research and development of Nicotine Addiction drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: 14 drugs in Pre-clinical phase, three drugs in Phase 1 and one drug in Phase 2
As of February 2020, the Nicotine Addiction pipeline remains robust with 18 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Nicotine Addiction treatment. Diverse types of targeted therapies are being explored through clinical trials including Alpha3 Beta4 nAChR partial agonist; Alpha3 beta4 nicotinic receptor antagonist; Cannabinoid receptor antagonist; Cannabinoid receptor modulators; glucocorticoid receptor antagonist; metabotropic glutamate receptor 2 (mGlu2) agonist; Nicotinic antagonists; opioid delta, mu and kappa receptor agonist; orexin-1 receptor antagonist; PDE7 inhibitor; peroxisome proliferator-activated gamma receptor agonist.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Nicotine Addiction drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
Nicotine Addiction pipeline drugs profiled in the report include- ATI-1013, ATI-3009, AP-202, AT-1001, SBP-0069330, Biologics for Nicotine Addiction, CTDP-002, CVSI-007 (cannabidiol + nicotine), Noribogaine, C4X3256, AM4113, AM6527, OMS405, OMS527, PT150, 18-Methoxycoronaridine (18-MC), orexin 1 antagonist for Nicotine Addiction, Vaccine for Nicotine Addiction
As of February 2020, the Nicotine Addiction pipeline remains robust with 18 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Nicotine Addiction treatment. Diverse types of targeted therapies are being explored through clinical trials including Alpha3 Beta4 nAChR partial agonist; Alpha3 beta4 nicotinic receptor antagonist; Cannabinoid receptor antagonist; Cannabinoid receptor modulators; glucocorticoid receptor antagonist; metabotropic glutamate receptor 2 (mGlu2) agonist; Nicotinic antagonists; opioid delta, mu and kappa receptor agonist; orexin-1 receptor antagonist; PDE7 inhibitor; peroxisome proliferator-activated gamma receptor agonist.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Nicotine Addiction drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
- The report scope comprises of both pre-clinical phase and clinical phase development drugs for Nicotine Addiction development
- Nicotine Addiction pipeline compounds and molecules under study by both large scale and small companies are included in the report
- Nicotine Addiction pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
- Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
- Further, orphan drug status, fast track designation, different grants awarded and special status for Nicotine Addiction pipeline candidates included
- Business overview and snapshot of all companies involved in Nicotine Addiction pipeline are included
- Latest market and pipeline developments are provided in the report
Nicotine Addiction pipeline drugs profiled in the report include- ATI-1013, ATI-3009, AP-202, AT-1001, SBP-0069330, Biologics for Nicotine Addiction, CTDP-002, CVSI-007 (cannabidiol + nicotine), Noribogaine, C4X3256, AM4113, AM6527, OMS405, OMS527, PT150, 18-Methoxycoronaridine (18-MC), orexin 1 antagonist for Nicotine Addiction, Vaccine for Nicotine Addiction
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Nicotine Addiction Condition
2.3 Nicotine Addiction Pipeline Snapshot, 2020
2.4 Companies investing in Nicotine Addiction pipeline therapeutics
2.5 Phase wise Nicotine Addiction Pipeline Candidates
2.6 Most Researched Mechanism of Action of Nicotine Addiction Pipeline Products
2.7 Route of Administration of Nicotine Addiction Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Antidote Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.2 Assuage Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.3 Astraea Therapeutics LLC Overview, Contacts and ASD Pipeline Drugs
3.4 Camino Pharma LLC Overview, Contacts and ASD Pipeline Drugs
3.5 Cessation Therapeutics LLC Overview, Contacts and ASD Pipeline Drugs
3.6 Chronos Therapeutics Ltd Overview, Contacts and ASD Pipeline Drugs
3.7 CV Sciences Inc Overview, Contacts and ASD Pipeline Drugs
3.8 DemeRx Inc Overview, Contacts and ASD Pipeline Drugs
3.9 Indivior Plc Overview, Contacts and ASD Pipeline Drugs
3.10 MAKScientific LLC Overview, Contacts and ASD Pipeline Drugs
3.11 Omeros Corp Overview, Contacts and ASD Pipeline Drugs
3.12 Palisades Therapeutics Overview, Contacts and ASD Pipeline Drugs
3.13 Savant HWP Inc Overview, Contacts and ASD Pipeline Drugs
3.14 Sosei Heptares Overview, Contacts and ASD Pipeline Drugs
3.15 Tria Bioscience Corp Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 ATI-1013 Drug Details
4.1.1 ATI-1013 Current Status
4.1.2 ATI-1013 Drug Overview
4.1.3 ATI-1013 Mechanism of Action
4.1.4 ATI-1013 Licensing/Collaboration Companies
4.1.5 ATI-1013 Clinical Trials
4.2 ATI-3009 Drug Details
4.2.1 ATI-3009 Current Status
4.2.2 ATI-3009 Drug Overview
4.2.3 ATI-3009 Mechanism of Action
4.2.4 ATI-3009 Licensing/Collaboration Companies
4.2.5 ATI-3009 Clinical Trials
4.3 AP-202 Drug Details
4.3.1 AP-202 Current Status
4.3.2 AP-202 Drug Overview
4.3.3 AP-202 Mechanism of Action
4.3.4 AP-202 Licensing/Collaboration Companies
4.3.5 AP-202 Clinical Trials
4.4 AT-1001 Drug Details
4.4.1 AT-1001 Current Status
4.4.2 AT-1001 Drug Overview
4.4.3 AT-1001 Mechanism of Action
4.4.4 AT-1001 Licensing/Collaboration Companies
4.4.5 AT-1001 Clinical Trials
4.5 SBP-0069330 Drug Details
4.5.1 SBP-0069330 Current Status
4.5.2 SBP-0069330 Drug Overview
4.5.3 SBP-0069330 Mechanism of Action
4.5.4 SBP-0069330 Licensing/Collaboration Companies
4.5.5 SBP-0069330 Clinical Trials
4.6 Biologics for Nicotine Addiction Drug Details
4.6.1 Biologics for Nicotine Addiction Current Status
4.6.2 Biologics for Nicotine Addiction Drug Overview
4.6.3 Biologics for Nicotine Addiction Mechanism of Action
4.6.4 Biologics for Nicotine Addiction Licensing/Collaboration Companies
4.6.5 Biologics for Nicotine Addiction Clinical Trials
4.7 CTDP-002 Drug Details
4.7.1 CTDP-002 Current Status
4.7.2 CTDP-002 Drug Overview
4.7.3 CTDP-002 Mechanism of Action
4.7.4 CTDP-002 Licensing/Collaboration Companies
4.7.5 CTDP-002 Clinical Trials
4.8 CVSI-007 (cannabidiol + nicotine) Drug Details
4.8.1 CVSI-007 (cannabidiol + nicotine) Current Status
4.8.2 CVSI-007 (cannabidiol + nicotine) Drug Overview
4.8.3 CVSI-007 (cannabidiol + nicotine) Mechanism of Action
4.8.4 CVSI-007 (cannabidiol + nicotine) Licensing/Collaboration Companies
4.8.5 CVSI-007 (cannabidiol + nicotine) Clinical Trials
4.9 Noribogaine Drug Details
4.9.1 Noribogaine Current Status
4.9.2 Noribogaine Drug Overview
4.9.3 Noribogaine Mechanism of Action
4.9.4 Noribogaine Licensing/Collaboration Companies
4.9.5 Noribogaine Clinical Trials
4.10 C4X3256 Drug Details
4.10.1 C4X3256 Current Status
4.10.2 C4X3256 Drug Overview
4.10.3 C4X3256 Mechanism of Action
4.10.4 C4X3256 Licensing/Collaboration Companies
4.10.5 C4X3256 Clinical Trials
4.11 AM4113 Drug Details
4.11.1 AM4113 Current Status
4.11.2 AM4113 Drug Overview
4.11.3 AM4113 Mechanism of Action
4.11.4 AM4113 Licensing/Collaboration Companies
4.11.5 AM4113 Clinical Trials
4.12 AM6527 Drug Details
4.12.1 AM6527 Current Status
4.12.2 AM6527 Drug Overview
4.12.3 AM6527 Mechanism of Action
4.12.4 AM6527 Licensing/Collaboration Companies
4.12.5 AM6527 Clinical Trials
4.13 OMS405 Drug Details
4.13.1 OMS405 Current Status
4.13.2 OMS405 Drug Overview
4.13.3 OMS405 Mechanism of Action
4.13.4 OMS405 Licensing/Collaboration Companies
4.13.5 OMS405 Clinical Trials
4.14 OMS527 Drug Details
4.14.1 OMS527 Current Status
4.14.2 OMS527 Drug Overview
4.14.3 OMS527 Mechanism of Action
4.14.4 OMS527 Licensing/Collaboration Companies
4.14.5 OMS527 Clinical Trials
4.15 PT150 Drug Details
4.15.1 PT150 Current Status
4.15.2 PT150 Drug Overview
4.15.3 PT150 Mechanism of Action
4.15.4 PT150 Licensing/Collaboration Companies
4.15.5 PT150 Clinical Trials
4.16 18-Methoxycoronaridine (18-MC) Drug Details
4.16.1 18-Methoxycoronaridine (18-MC) Current Status
4.16.2 18-Methoxycoronaridine (18-MC) Drug Overview
4.16.3 18-Methoxycoronaridine (18-MC) Mechanism of Action
4.16.4 18-Methoxycoronaridine (18-MC) Licensing/Collaboration Companies
4.16.5 18-Methoxycoronaridine (18-MC) Clinical Trials
4.17 orexin 1 antagonist for Nicotine Addiction Drug Details
4.17.1 orexin 1 antagonist for Nicotine Addiction Current Status
4.17.2 orexin 1 antagonist for Nicotine Addiction Drug Overview
4.17.3 orexin 1 antagonist for Nicotine Addiction Mechanism of Action
4.17.4 orexin 1 antagonist for Nicotine Addiction Licensing/Collaboration Companies
4.17.5 orexin 1 antagonist for Nicotine Addiction Clinical Trials
4.18 Vaccine for Nicotine Addiction Drug Details
4.18.1 Vaccine for Nicotine Addiction Current Status
4.18.2 Vaccine for Nicotine Addiction Drug Overview
4.18.3 Vaccine for Nicotine Addiction Mechanism of Action
4.18.4 Vaccine for Nicotine Addiction Licensing/Collaboration Companies
4.18.5 Vaccine for Nicotine Addiction Clinical Trials
5. LATEST NICOTINE ADDICTION PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Nicotine Addiction Condition
2.3 Nicotine Addiction Pipeline Snapshot, 2020
2.4 Companies investing in Nicotine Addiction pipeline therapeutics
2.5 Phase wise Nicotine Addiction Pipeline Candidates
2.6 Most Researched Mechanism of Action of Nicotine Addiction Pipeline Products
2.7 Route of Administration of Nicotine Addiction Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Antidote Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.2 Assuage Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.3 Astraea Therapeutics LLC Overview, Contacts and ASD Pipeline Drugs
3.4 Camino Pharma LLC Overview, Contacts and ASD Pipeline Drugs
3.5 Cessation Therapeutics LLC Overview, Contacts and ASD Pipeline Drugs
3.6 Chronos Therapeutics Ltd Overview, Contacts and ASD Pipeline Drugs
3.7 CV Sciences Inc Overview, Contacts and ASD Pipeline Drugs
3.8 DemeRx Inc Overview, Contacts and ASD Pipeline Drugs
3.9 Indivior Plc Overview, Contacts and ASD Pipeline Drugs
3.10 MAKScientific LLC Overview, Contacts and ASD Pipeline Drugs
3.11 Omeros Corp Overview, Contacts and ASD Pipeline Drugs
3.12 Palisades Therapeutics Overview, Contacts and ASD Pipeline Drugs
3.13 Savant HWP Inc Overview, Contacts and ASD Pipeline Drugs
3.14 Sosei Heptares Overview, Contacts and ASD Pipeline Drugs
3.15 Tria Bioscience Corp Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 ATI-1013 Drug Details
4.1.1 ATI-1013 Current Status
4.1.2 ATI-1013 Drug Overview
4.1.3 ATI-1013 Mechanism of Action
4.1.4 ATI-1013 Licensing/Collaboration Companies
4.1.5 ATI-1013 Clinical Trials
4.2 ATI-3009 Drug Details
4.2.1 ATI-3009 Current Status
4.2.2 ATI-3009 Drug Overview
4.2.3 ATI-3009 Mechanism of Action
4.2.4 ATI-3009 Licensing/Collaboration Companies
4.2.5 ATI-3009 Clinical Trials
4.3 AP-202 Drug Details
4.3.1 AP-202 Current Status
4.3.2 AP-202 Drug Overview
4.3.3 AP-202 Mechanism of Action
4.3.4 AP-202 Licensing/Collaboration Companies
4.3.5 AP-202 Clinical Trials
4.4 AT-1001 Drug Details
4.4.1 AT-1001 Current Status
4.4.2 AT-1001 Drug Overview
4.4.3 AT-1001 Mechanism of Action
4.4.4 AT-1001 Licensing/Collaboration Companies
4.4.5 AT-1001 Clinical Trials
4.5 SBP-0069330 Drug Details
4.5.1 SBP-0069330 Current Status
4.5.2 SBP-0069330 Drug Overview
4.5.3 SBP-0069330 Mechanism of Action
4.5.4 SBP-0069330 Licensing/Collaboration Companies
4.5.5 SBP-0069330 Clinical Trials
4.6 Biologics for Nicotine Addiction Drug Details
4.6.1 Biologics for Nicotine Addiction Current Status
4.6.2 Biologics for Nicotine Addiction Drug Overview
4.6.3 Biologics for Nicotine Addiction Mechanism of Action
4.6.4 Biologics for Nicotine Addiction Licensing/Collaboration Companies
4.6.5 Biologics for Nicotine Addiction Clinical Trials
4.7 CTDP-002 Drug Details
4.7.1 CTDP-002 Current Status
4.7.2 CTDP-002 Drug Overview
4.7.3 CTDP-002 Mechanism of Action
4.7.4 CTDP-002 Licensing/Collaboration Companies
4.7.5 CTDP-002 Clinical Trials
4.8 CVSI-007 (cannabidiol + nicotine) Drug Details
4.8.1 CVSI-007 (cannabidiol + nicotine) Current Status
4.8.2 CVSI-007 (cannabidiol + nicotine) Drug Overview
4.8.3 CVSI-007 (cannabidiol + nicotine) Mechanism of Action
4.8.4 CVSI-007 (cannabidiol + nicotine) Licensing/Collaboration Companies
4.8.5 CVSI-007 (cannabidiol + nicotine) Clinical Trials
4.9 Noribogaine Drug Details
4.9.1 Noribogaine Current Status
4.9.2 Noribogaine Drug Overview
4.9.3 Noribogaine Mechanism of Action
4.9.4 Noribogaine Licensing/Collaboration Companies
4.9.5 Noribogaine Clinical Trials
4.10 C4X3256 Drug Details
4.10.1 C4X3256 Current Status
4.10.2 C4X3256 Drug Overview
4.10.3 C4X3256 Mechanism of Action
4.10.4 C4X3256 Licensing/Collaboration Companies
4.10.5 C4X3256 Clinical Trials
4.11 AM4113 Drug Details
4.11.1 AM4113 Current Status
4.11.2 AM4113 Drug Overview
4.11.3 AM4113 Mechanism of Action
4.11.4 AM4113 Licensing/Collaboration Companies
4.11.5 AM4113 Clinical Trials
4.12 AM6527 Drug Details
4.12.1 AM6527 Current Status
4.12.2 AM6527 Drug Overview
4.12.3 AM6527 Mechanism of Action
4.12.4 AM6527 Licensing/Collaboration Companies
4.12.5 AM6527 Clinical Trials
4.13 OMS405 Drug Details
4.13.1 OMS405 Current Status
4.13.2 OMS405 Drug Overview
4.13.3 OMS405 Mechanism of Action
4.13.4 OMS405 Licensing/Collaboration Companies
4.13.5 OMS405 Clinical Trials
4.14 OMS527 Drug Details
4.14.1 OMS527 Current Status
4.14.2 OMS527 Drug Overview
4.14.3 OMS527 Mechanism of Action
4.14.4 OMS527 Licensing/Collaboration Companies
4.14.5 OMS527 Clinical Trials
4.15 PT150 Drug Details
4.15.1 PT150 Current Status
4.15.2 PT150 Drug Overview
4.15.3 PT150 Mechanism of Action
4.15.4 PT150 Licensing/Collaboration Companies
4.15.5 PT150 Clinical Trials
4.16 18-Methoxycoronaridine (18-MC) Drug Details
4.16.1 18-Methoxycoronaridine (18-MC) Current Status
4.16.2 18-Methoxycoronaridine (18-MC) Drug Overview
4.16.3 18-Methoxycoronaridine (18-MC) Mechanism of Action
4.16.4 18-Methoxycoronaridine (18-MC) Licensing/Collaboration Companies
4.16.5 18-Methoxycoronaridine (18-MC) Clinical Trials
4.17 orexin 1 antagonist for Nicotine Addiction Drug Details
4.17.1 orexin 1 antagonist for Nicotine Addiction Current Status
4.17.2 orexin 1 antagonist for Nicotine Addiction Drug Overview
4.17.3 orexin 1 antagonist for Nicotine Addiction Mechanism of Action
4.17.4 orexin 1 antagonist for Nicotine Addiction Licensing/Collaboration Companies
4.17.5 orexin 1 antagonist for Nicotine Addiction Clinical Trials
4.18 Vaccine for Nicotine Addiction Drug Details
4.18.1 Vaccine for Nicotine Addiction Current Status
4.18.2 Vaccine for Nicotine Addiction Drug Overview
4.18.3 Vaccine for Nicotine Addiction Mechanism of Action
4.18.4 Vaccine for Nicotine Addiction Licensing/Collaboration Companies
4.18.5 Vaccine for Nicotine Addiction Clinical Trials
5. LATEST NICOTINE ADDICTION PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
